Adagio Medical Holdings (ADGM)
NASDAQ:ADGM
Want to see ADGM full AI Analyst Report?
Top Page
Adagio Medical Holdings
(NASDAQ:ADGM)
Select Model
Select Model
Rating:54Neutral
Price Target:
$1.50
▲(38.89% Upside)
Action:ReiteratedDate:04/15/26
The score is held back primarily by weak financial performance (minimal revenue, sustained losses, and ongoing cash burn with elevated leverage). Technicals are a key offset with price trending above major moving averages and positive momentum, while valuation remains constrained by losses (negative P/E). A positive FDA IDE trial expansion supports the outlook but does not yet change near-term financial risk.
Positive Factors
Regulatory IDE Expansion
The FDA IDE expansion institutionalizes clinical evaluation of the next‑generation vCLAS system and enables a prospective multi‑center sub-study. This creates a durable pathway to regulatory validation and clinical evidence, which is prerequisite to commercial adoption and sustained market entry over months to years.
Negative Factors
No Commercial Revenue
Zero reported revenue in 2025 signals absence of commercial traction and means the company remains dependent on clinical progress and external financing. Lack of product revenues prevents internal funding of R&D and scale-up, leaving long‑term viability contingent on successful trial outcomes and market entry.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory IDE Expansion
The FDA IDE expansion institutionalizes clinical evaluation of the next‑generation vCLAS system and enables a prospective multi‑center sub-study. This creates a durable pathway to regulatory validation and clinical evidence, which is prerequisite to commercial adoption and sustained market entry over months to years.
Read all positive factors
Adagio Medical Holdings (ADGM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$31.76M
Dividend YieldN/A
Average Volume (3M)152.12K
Price to Earnings (P/E)―
Beta (1Y)-0.39
Revenue Growth-70.54%
EPS Growth70.03%
CountryUS
Employees80
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.21
Shares Outstanding22,210,459
10 Day Avg. Volume84,483
30 Day Avg. Volume152,119
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.39
Price to Sales (P/S)0.00
P/FCF Ratio-0.89
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-30.67
Enterprise Value/Ebitda-1.15
Forecast
1Y Price Target
$3.50Price Target Upside224.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.95
Revenue Forecast (FY)N/A
Adagio Medical Holdings Business Overview & Revenue Model
Company Description
Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including...
How the Company Makes Money
null...
Adagio Medical Holdings Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
22
Negative
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 269.00K | 300.00K | 189.00K | 270.00K |
| Gross Profit | -684.00K | -1.67M | -1.01M | -686.00K | -888.00K |
| EBITDA | -21.89M | -62.48M | -27.41M | -23.04M | -19.60M |
| Net Income | -25.08M | -53.76M | -38.15M | -23.67M | -19.94M |
Balance Sheet | |||||
| Total Assets | 43.25M | 48.45M | 6.83M | 8.70M | 21.44M |
| Cash, Cash Equivalents and Short-Term Investments | 17.11M | 20.59M | 1.38M | 5.55M | 18.85M |
| Total Debt | 21.76M | 16.27M | 38.40M | 9.80M | 0.00 |
| Total Liabilities | 30.85M | 28.54M | 138.85M | 104.57M | 94.06M |
| Stockholders Equity | 12.40M | 19.91M | -132.02M | -95.88M | -72.62M |
Cash Flow | |||||
| Free Cash Flow | -19.39M | -31.11M | -25.98M | -22.90M | -20.58M |
| Operating Cash Flow | -19.01M | -29.46M | -25.65M | -22.41M | -19.31M |
| Investing Cash Flow | -374.00K | -1.65M | -340.00K | -500.00K | -1.27M |
| Financing Cash Flow | 16.13M | 15.63M | 21.88M | 9.53M | 130.00K |
Adagio Medical Holdings Technical Analysis
Positive
1.08
Price Trends
1.12
Positive
1.04
Positive
1.26
Positive
Market Momentum
0.11
Negative
63.69
Neutral
61.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADGM, the sentiment is Positive. The current price of 1.08 is below the 20-day moving average (MA) of 1.29, below the 50-day MA of 1.12, and below the 200-day MA of 1.26, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 63.69 is Neutral, neither overbought nor oversold. The STOCH value of 61.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ADGM.
Adagio Medical Holdings Risk Analysis
Adagio Medical Holdings disclosed 65 risk factors in its most recent earnings report. Adagio Medical Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Adagio Medical Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $31.76M | -1.58 | -312.04% | ― | -70.54% | 70.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $55.35M | -0.55 | 129.49% | ― | -25.18% | -9.71% | |
45 Neutral | $59.55M | -1.01 | 1.02% | ― | -99.28% | -46.17% | |
44 Neutral | $15.39M | ― | -335.47% | ― | 18.76% | 60.09% | |
43 Neutral | $5.12M | -0.07 | -70.27% | ― | -87.84% | 29.16% | |
41 Neutral | $22.14M | -2.02 | -279.06% | ― | ― | ― |
* Healthcare Sector Average
ADGM
Adagio Medical Holdings
1.55
0.35
29.17%
CODX
Co-Diagnostics
1.56
-9.10
-85.36%
PAVM
PAVmed
9.12
-10.53
-53.59%
VVOS
Vivos Therapeutics
0.97
-1.23
-55.73%
IINN
Inspira Technologies Oxy BHN
0.50
-0.07
-12.63%
COCH
Envoy Medical
0.71
-0.60
-45.95%
Adagio Medical Holdings Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Adagio Medical Expands IDE Trial for Next-Generation vCLAS System
Positive
Apr 8, 2026
On April 8, 2026, Adagio Medical announced that the U.S. Food and Drug Administration granted Investigational Device Exemption approval to expand its FULCRUM-VT trial to study the next-generation vCLAS Ultra-Low Temperature Ablation Ventricular Ab...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.